Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Could the controversial drug ivermectin save lives?

By Brian Buntz | June 22, 2021

coronavirus COVID-19 Merck

[Photo by Fusion Medical Animation on Unsplash]

The antiparasitic drug ivermectin holds promise as a COVID-19 treatment, according to a new study published in the American Journal of Therapeutics.

The study authors conclude that ivermectin could reduce the risk of COVID-19-related death with moderate-certainty evidence. “Using ivermectin early in the clinical course may reduce numbers progressing to severe disease,” they conclude, adding that the drug is “likely to have a significant impact on the SARS-CoV-2 pandemic globally.”

The meta-analysis analyzed databases up to April 2021, drawing from 24 randomized controlled trials with 3,406 patients. 

Another study published in Lancet found a concentration-dependent antiviral activity of oral high-dose ivermectin in a trial involving 45 patients.  

Many experts, however, have voiced skepticism regarding the use of ivermectin as a COVID-19 treatment. In May, Health Feedback concluded that ivermectin did not slow the infection rate in countries with high COVID-19 caseloads. 

A randomized study published in JAMA concluded that ivermectin did not appear to be an efficacious COVID-19 treatment for mild COVID-19, but critics pointed to methodological flaws in that study. 

FDA has warned consumers of using the drug to treat or prevent COVID-19, as the agency has not authorized the use of the drug as a treatment for the novel coronavirus, and large doses of the drug can cause serious side effects. 

WHO and NIH have come to similar conclusions regarding the use of ivermectin as a COVID-19 treatment. In March, WHO  concluded that ivermectin should only be used as a COVID-19 treatment in clinical trials. 

In February, ivermectin manufacturer Merck concluded there was no solid scientific basis for using ivermectin as a COVID-19 treatment.  

Tell Us What You Think! Cancel reply

Related Articles Read More >

vaccine
Will COVID-19 vaccines be updated by fall? 
COVID-19 vaccine
Young children in U.S. now eligible for COVID-19 vaccination
Florida
Florida chooses to not pre-order COVID-19 vaccines for young children
Pfizer logo
Pfizer to spend $120M to make COVID-19 oral treatment in U.S.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards